User profiles for Marc Feldmann

Marc Feldmann

Imperial College and Oxford
Verified email at kennedy.ox.ac.uk
Cited by 96655

[HTML][HTML] Infliximab and methotrexate in the treatment of rheumatoid arthritis

…, M Weisman, P Emery, M Feldmann… - … England Journal of …, 2000 - Mass Medical Soc
Background Neutralization of tumor necrosis factor α (TNF-α) for three to six months reduces
the symptoms and signs of rheumatoid arthritis. However, the capacity of this approach to …

[HTML][HTML] An inflammatory cytokine signature predicts COVID-19 severity and survival

…, D Reich, K Sigel, C Cordon-Cardo, M Feldmann… - Nature medicine, 2020 - nature.com
Several studies have revealed that the hyper-inflammatory response induced by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a major cause of disease severity …

Role of cytokines in rheumatoid arthritis

M Feldmann, FM Brennan… - Annual review of …, 1996 - annualreviews.org
▪ Abstract Analysis of cytokine mRNA and protein in rheumatoid arthritis tissue revealed that
many proinflammatory cytokines such as TNFα, IL-1, IL-6, GM-CSF, and chemokines such …

Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a …

…, J Smolen, P Emery, G Harriman, M Feldmann… - The Lancet, 1999 - thelancet.com
Background Not all patients with rheumatoid arthritis can tolerate or respond to methotrexate,
a standard treatment for this disease. There is evidence that antitumour necrosis factor α (…

Therapeutic efficacy of multiple intravenous infusions of anti‐tumor necrosis factor α monoclonal antibody combined with low‐dose weekly methotrexate in rheumatoid …

…, JN Woody, TF Schaible, M Feldmann - … : Official Journal of …, 1998 - Wiley Online Library
Objective To evaluate the efficacy, pharmacokinetics, immunogenicity, and safety of multiple
infusions of a chimeric monoclonal anti‐tumor necrosis factor α antibody (cA2) (infliximab; …

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

MJ Elliott, RN Maini, M Feldmann… - Arthritis & …, 1993 - Wiley Online Library
Objective. To evaluate the safety and efficacy of a chimeric monoclonal antibody to tumor
necrosis factor α (TNFα) in the treatment of patients with rheumatoid arthritis (RA). Methods. …

Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis.

RO Williams, M Feldmann… - Proceedings of the …, 1992 - National Acad Sciences
There is considerable evidence implicating tumor necrosis factor alpha (TNF-alpha) in the
pathogenesis of rheumatoid arthritis. This evidence is based not only on the universal …

Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis

…, A Jackson, D Chantry, R Maini, M Feldmann - The Lancet, 1989 - Elsevier
The effect of tumour necrosis factor (TNFα) antibodies on synovial cell interleukin-1 (IL-1)
production was investigated in 7 patients with rheumatoid arthritis and in 7 with osteoarthritis. …

TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases

M Feldmann, RN Maini - Nature medicine, 2003 - nature.com
As a medical student in the late 1960s in Australia, I realized that we knew very little about
the mechanisms of disease, and I was eager to learn more. In Melbourne, the premier …

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis

MJ Elliott, RN Maini, M Feldmann, JR Kalden, C Antoni… - The Lancet, 1994 - Elsevier
Tumour necrosis factor α (TNFα) is a critical inflammatory mediator in rheumatoid arthritis,
and may therefore be a useful target for specific immunotherapy. In support of this hypothesis, …